+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Market Spotlight: Celiac Disease

  • ID: 4533530
  • Report
  • November 2019
  • 30 pages
  • Datamonitor Healthcare
1 of 2
This Market Spotlight report covers the Celiac Disease market, comprising key pipeline drugs, clinical trials, upcoming events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals.

Key Takeaways
  • The author estimates that in 2017, there were approximately 89.9 million prevalent cases of celiac disease worldwide, and forecasts that number to increase to 98.8 million prevalent cases by 2026.
  • Prevalence of celiac disease is highest in Europe and Northern America, and lowest in Africa and Oceania. The majority of industry-sponsored drugs in active clinical development for celiac disease are in Phase II, with only one drug in Phase III.
  • Therapies in development for celiac disease focus on targets such as zonulin and zonulin receptor, interleukin-15, interleukin-15 receptor, and gluten. Pipeline drugs for celiac disease are administered via the oral and intravenous routes.
  • The release of topline Phase III trial results for INN-202 is the only high-impact upcoming event in the celiac disease space. The overall likelihood of approval of a Phase I autoimmune/immunology asset is 13.6%, and the average probability a drug advances from Phase III is 68.3%. Drugs, on average, take 9.0 years from Phase I to approval in the overall autoimmune/immunology space.
  • There have been seven licensing and asset acquisition deals involving celiac disease drugs during 2014–19. The largest deal during the period was the $800m collaboration and license agreement signed in May 2019 between Parvus and Genentech to develop, manufacture, and commercialize novel Navacim therapeutics for the treatment of inflammatory bowel disease, autoimmune liver diseases, and celiac disease.
  • The distribution of clinical trials across Phase I–IV indicates that the vast majority of trials for celiac disease have been in the mid and late phases of development, with 91% of trials in Phase II–III, and only 9% in Phase I.
  • The US has the highest number of celiac disease clinical trials globally. Clinical trial activity in the celiac disease space is dominated by completed trials. Innovate Biopharmaceuticals has the highest number of completed clinical trials for celiac disease, with six trials.
  • Innovate Biopharmaceuticals leads industry sponsors with the highest overall number of clinical trials for celiac disease.
Note: Product cover images may vary from those shown
2 of 2
Contents

Overview

Key Takeaways

Disease Background
  • Subtypes
Treatment

Epidemiology

Pipeline Drugs

Recent Events and Analyst Opinion
  • TAK-101 for Celiac Disease (October 21, 2019)
Key Upcoming Events

Probability of Success

Licensing and Asset Acquisition Deals
  • Takeda Adds Celiac Disease Candidate To GI Efforts
  • Anokion Acquires Its Own Spinout, Kanyos
  • GSK Buys One Of Eight Firms Formed In VC Partnership With Avalon
  • Parvus, Genentech Collaborate On IBD, Celiac And Liver Disease
Clinical Trial Landscape
  • Sponsors by status
  • Sponsors by phase
  • Phase II Study Shows Antigen-Specific Immune Tolerance Is Possible In Autoimmune Diseases
Bibliograpy

Appendix

List of Figures
Figure 1: Trends in prevalent cases of celiac disease, 2017-26
Figure 2: Overview of pipeline drugs for celiac disease in the US
Figure 3: Pipeline drugs for celiac disease, by company
Figure 4: Pipeline drugs for celiac disease, by drug type
Figure 5: Pipeline drugs for celiac disease, by classification
Figure 6: TAK-101 for Celiac Disease (October 21, 2019): Phase IIa - Safety & Efficacy
Figure 7: Key upcoming events in celiac disease
Figure 8: Probability of success in the celiac disease pipeline
Figure 9: Licensing and asset acquisition deals in celiac disease, 2014-19
Figure 10: Clinical trials in celiac disease
Figure 11: Top 10 drugs for clinical trials in celiac disease
Figure 12: Top 10 companies for clinical trials in celiac disease
Figure 13: Trial locations in celiac disease
Figure 14: Celiac disease trials status
Figure 15: Celiac disease trials sponsors, by phase

List of Tables
Table 1: Prevalent cases of celiac disease, 2017-26
Table 2: Prevalence proportions of celiac disease, by age group, 2017
Table 3: Pipeline drugs for celiac disease in the US
Table 4: TAK-101 for Celiac Disease (October 21, 2019)
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll